Biogen halted trial could boost M&A activity, says analyst

3:55 PM ET Thu, 21 March 2019

Jared Holz, healthcare strategist at Jefferies, and Paul Matteis, co-head of biotech research at Stifel, discuss Biogen after shares of the company plunged on Thursday.